Hims & Hers Health, Inc. has transformed from a niche obesity company into a significant healthcare ecosystem participant through its partnership with Novo Nordisk. Despite challenges like margin compression and earnings misses, the company aims to reach $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030 by expanding its platform. The stock trades at about 2 times sales, which is lower than typical sector valuations, while short interest remains high, indicating potential for further stock covering. This shift marks a notable change in investor perception and positions Hims & Hers for substantial growth in the healthcare market.

More News (HIMS)

Hims & Hers stays attractive at $33 despite weak Q1, boosted by Novo Nordisk deal and growth plans.

Hims & Hers remains an appealing investment at $33 per share, supported by a renewed partnership with Novo Nordisk and unique access to patient demand. Although Q1 2026 results showed only 4% revenue growth, declining margins, and a net loss, the com...

Market News

Bullish

2 days ago

Novo Nordisk deal boosts Hims & Hers into key healthcare player with $6.5B revenue goal by 2030.

More News (HIMS)

Hims & Hers stays attractive at $33 despite weak Q1, boosted by Novo Nordisk deal and growth plans.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

Novo Nordisk deal boosts Hims & Hers into key healthcare player with $6.5B revenue goal by 2030.

More News (HIMS)

Hims & Hers stays attractive at $33 despite weak Q1, boosted by Novo Nordisk deal and growth plans.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App